Carol L. DiBerardino

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a press release.The nonopioid analgesic suzetrigine (Journavx, Vertex Pharmaceuticals), becomes the first drug to be approved in a new class of pain management medications known as sodium channel blockers. The agent reduces pain by targeting a pain-signaling pathway

In a phase 2/3 clinical trial, treatment with buntanetap was linked to cognitive gains as well as tau reduction at 12 weeks in those exhibiting mild to moderate symptoms of Alzheimer’s disease, according to the drug’s manufacturer.In a press release, Annovis Bio stated that the United States-based study — which was reviewed by the Data and Safety Monitoring Board in October 2023

A European clinical stage biotech company announced dosing of the first patient in cohort 2 of its ongoing phase 1/2 GATEWAY clinical trial of lead candidate VTX-801 to treat Wilson’s disease. According to a release from Vivet Therapeutics, GATEWAY is a nonrandomized, open-label study conducted across several clinical sites in the United States, United Kingdom, Germany and Denmark. The

The FDA has granted rare pediatric disease designation to an alpha-kinase 1 inhibitor to treat patients with retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache, or ROSAH, syndrome.According to a press release from developer Drug Farm, DF-003 is currently being evaluated in a phase 1 clinical trial assessing safety and pharmacokinetics in healthy volunteers.

The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme’s Enhanze drug delivery technology, to treat chronic inflammatory demyelinating polyneuropathy in adults.According to a Takeda press release, Hyqvia is the only currently available FDA-approved combination of immunoglobulin (IG) and hyaluronidase for adults with chronic inflammatory demyelinating polyneuropathy

The FDA has approved once-daily Ingrezza capsules for adults with chorea associated with Huntington’s disease. According to a release from Neurocrine Biosciences Inc., the selective vesicular monoamine transporter 2 inhibitor Ingrezza (valbenazine, Neurocrine) can be adjusted by a patient’s health care provider based on response and tolerability, with no complex titration.

C2N Diagnostics released the PrecivityAD2 blood test, which uses positron emission tomography scans and cerebrospinal fluid tests to assist in accurate diagnosis for those presenting with signs or symptoms of Alzheimer’s disease.According to a company release, in a clinical validation study involving two independent cohorts of 583 patients with cognitive impairment using amyloid positron

The FDA has approved an expanded indication for a proprietary neurostimulation technology to treat those with severe obstructive sleep apnea. According to a release from Inspire Medical Systems Inc, the regulatory body’s approval includes an increase on the upper limit of the therapeutic’s Apnea Hypopnea Index (AHI) to 100 events per hour from 65, as well as raising the BMI label

Women appeared significantly underrepresented as first authors of thousands of randomized controlled trials compared with men, according to study results published in Contemporary Clinical Trials.

The V Foundation announced a multimillion dollar inaugural program to increase representation of women in cancer research.